Andrey Zarur - GreenLight Biosciences President, CoFounder
| GRNAWDelisted Stock | USD 0.02 0 25.00% |
Insider
Andrey Zarur is President, CoFounder of GreenLight Biosciences Holdings
| Age | 52 |
| Phone | 617 616 8188 |
| Web | https://greenlightbiosciences.com |
Similar Executives
| Found 7 records | INSIDER Age | ||
| Raphi Levy | Alpha Tau Medical | 39 | |
| Uzi Sofer | Alpha Tau Medical | 54 | |
| Amnon Gat | Alpha Tau Medical | 49 | |
| Robert MD | Alpha Tau Medical | 45 | |
| Pr Keisari | Alpha Tau Medical | 77 | |
| Ronen Segal | Alpha Tau Medical | 51 | |
| Pr Kelson | Alpha Tau Medical | 84 | |
GreenLight Biosciences Leadership Team
Elected by the shareholders, the GreenLight Biosciences' board of directors comprises two types of representatives: GreenLight Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of GreenLight. The board's role is to monitor GreenLight Biosciences' management team and ensure that shareholders' interests are well served. GreenLight Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, GreenLight Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Susan MBA, CFO Officer | ||
| Mark Singleton, Chief Health | ||
| Charu MBA, Chief Officer | ||
| Amin Khan, Human Officer | ||
| Thomas Crampton, Sr Affairs | ||
| Andrey Zarur, President, CoFounder | ||
| Carole MBA, Chief Officer | ||
| David Esq, Gen Sec | ||
| MSc MBA, CoFounder Health |
GreenLight Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is GreenLight Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Number Of Shares Shorted | 4.79 K | |||
| Revenue | 6.38 M | |||
| EBITDA | (153.99 M) | |||
| Net Income | (167.06 M) | |||
| Cash And Equivalents | 34.75 M | |||
| Cash Per Share | 10.01 X | |||
| Total Debt | 80.48 M | |||
| Debt To Equity | 9.81 % | |||
| Book Value Per Share | (61.86) X | |||
| Cash Flow From Operations | (136.73 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in GreenLight Stock
If you are still planning to invest in GreenLight Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GreenLight Biosciences' history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |